日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌：随机3期PHILA试验的长期生存结果

期刊:Bmj-British Medical Journal
影响因子:42.7
doi:10.1136/bmj-2025-087259
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial

比瑞西尼联合氟维司群治疗内分泌进展后的晚期乳腺癌：BRIGHT-2 III期随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2026.0318
Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Hu, Yan; Wang, Qiuli; Duan, Xianghui; Yang, Fan; Wang, Li; Xu, Binghe
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China

在中国开展的阿贝西利治疗HR+、HER2-乳腺癌患者的上市后前瞻性观察研究

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyag013
Ouyang, Quchang; Yuan, Peng; Liu, Jianxia; Teng, Yuee; Li, Zhihua; Ji, Xuening; Liu, Lina; Wang, Mopei; Zou, Liqun; Xu, Ling; Yang, Suisheng; Zhu, Zhenxin; Yang, Liu; Li, Jinnan; Liu, Qiang
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Chemokine-Like Receptor 1 Knockdown Suppresses Oral Squamous Cell Carcinoma Progression by Reducing Oxidative Phosphorylation.

趋化因子样受体 1 敲低通过减少氧化磷酸化抑制口腔鳞状细胞癌的进展。

期刊:International Dental Journal
影响因子:3.7
doi:10.1016/j.identj.2026.109479
Lin Yanzhu, Zhao Luodan, Huang Ying, Chen Yuee, Wan Quan, Lu Zhiyuan, Zhang Xiangsong
细胞生物学
磷酸化
发表日期：2026
文献求助 收藏

Long noncoding RNA SRRM2-AS1 mediates coronary artery damage in Kawasaki disease by promoting endothelial-to-mesenchymal transition.

长链非编码RNA SRRM2-AS1通过促进内皮-间质转化介导川崎病中的冠状动脉损伤。

期刊:Clinical and Experimental Medicine
影响因子:3.5
doi:10.1007/s10238-026-02103-9
Song Shiyang, Zhang Hui, Lin Renchao, Zhang Jingyi, Zhang Qianqian, Li Changhao, Xia Yushan, Zeng Jingjing, Lu Kongchang, Ge Donghui, Qiu Huixian, Niu Chao, Jia Chang, Zhang Chunxiang, He Yuee, Chu Maoping, Rong Xing
发表日期：2026
文献求助 收藏

Factors associated with clinical outcomes of breast cancer based on glucose metabolic activity of subcutaneous adipose tissue

基于皮下脂肪组织葡萄糖代谢活性的乳腺癌临床结局相关因素

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2026.1722085
Mai, Jinci; Wu, Huanhua; Wu, Wanwan; Zhou, Jinjun; Wu, Yuee; Duan, Xiaobei; Wu, Rizhao; Hu, Youzhu; Zhen, Zuowu; Huang, Binhao
肿瘤
肿瘤免疫
乳腺癌
代谢
发表日期：2026
文献求助 收藏

Interaction between illness cognitions and dyadic coping: a qualitative exploration of stress adaptation in young and middle-aged colorectal cancer patients and their spouses

疾病认知与夫妻共同应对的互动：对中青年结直肠癌患者及其配偶压力适应的定性探索

期刊:Supportive Care in Cancer
影响因子:3
doi:10.1007/s00520-026-10463-x
Sun, Qian; Xu, Peirong; Wen, Yuee; Ruan, Lei; Liu, Xuelan; Peng, Junsheng; Yorke, Janelle; Ho, Ka Yan
肿瘤
肠癌
肿瘤免疫
神经科学
发表日期：2026
文献求助 收藏

Biochemical indicators, physical activity, and functional performance in elderly CKD patients: A cross-sectional study

老年慢性肾脏病患者的生化指标、身体活动和功能表现：一项横断面研究

期刊:Science Progress
影响因子:2.9
doi:10.1177/00368504261417773
Wen, Quan; Ye, Qing; Sun, Yiming; Liu, Xinru; Yang, Jie; Men, Hui; Tan, Yuee; Yuan, Suyang; Dai, Yu
发表日期：2026
文献求助 收藏

An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial

一项开放标签、单臂、多中心 II 期临床试验，旨在评估 bireociclib 单药治疗既往接受过大量治疗的 HR 阳性、HER2 阴性晚期乳腺癌患者的疗效：BRIGHT-1 试验

期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.70009
Wang, Jiayu; Zhang, Qingyuan; Sun, Tao; Li, Huiping; Cheng, Ying; Tong, Zhongsheng; Li, Huihui; Li, Wei; Wang, Jingfen; Teng, Yuee; Wu, Xinhong; Cheng, Jing; Chen, Zhendong; Zhu, Zhengqiu; Wang, Li; Liu, Mingming; Duan, Xianghui; Xu, Lingmei; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis

Bireociclib联合氟维司群治疗HR+/HER2-晚期女性乳腺癌（内分泌治疗后进展）：BRIGHT-2 III期研究中期分析

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-58647-z
Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Liu, Fei; Duan, Xianghui; Wang, Shuya; Meng, Yaping; Wang, Li; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏